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Clinical trials are widely used as a means to test the efficacy
of treatments in cancer. The main statistical requirements of
a successful Phase III clinical trial are described by Peto et al.
(1976) as:
(i) that patients are allocated their treatment in such a
way as to avoid bias in the treatment comparison -
this requires some form of randomisation;
(ii) that the number of patients entered is sufficiently large
to give a reasonable chance of detecting a clinically
worthwhile difference; and
(iii) that the data gathered from the trial have a high level
of reliability and completeness.
The first two of these requirements have received lengthy
discussion in the literature (Pocock, 1983; Buyse et al., 1984;
Freedman, 1989). Thus an international survey of cancer
trials conducted on behalf of the Worth Health Organisation
(WHO) has shown that, while randomisation is now com-
monly employed, it is less usual to find adequate numbers of
patients in trials (Pocock, 1978). This was confirmed to be
the case in the United Kingdom (Tate et al., 1979). Realisa-
tion of this lack of patient numbers has led to greater efforts
to increase trial size, with the formation of national and
international cooperative groups such as the United Kingdom
Childhood Cancer Study Group (UKCCSG), United King-
dom Coordinating Committee for Cancer Research (UKC-
CCR) and the European Organisation for Research and
Treatment of Cancer (EORTC), to organise multicentre
studies. Commensurate with this effort, there has been a
growth in the number and size of Cancer Trials Offices,
providing statistical, computing and data management sup-
port, to coordinate the conduct of these trials.
Less attention has been paid to the third requirement of
data reliability and completeness. Along with the growth in
size of clinical trials comes a corresponding increase in the
amount of data handling although an established principle,
particularly in large studies, is to collect only information
germane to the main question under investigation which is
often survival.
Nevertheless, in cancer trials follow-up is often prolonged
with the consequential accumulation of substantial data per
patient. In addition survival time may not constitute the only
endpoint of interest. For example, in adjuvant studies where
there may be only a small survival benefit for a drug, the
longitudinal assessment of toxicity from chemotherapy is
particularly important. Therefore, as well as initial details
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and disease characteristics of each patient, and the treatment
given, cancer trials often require the recording of substantial
follow-up information including toxicity data and measures
of quality of life. The volume of data collected makes quality
control a real problem and one that needs careful planning
from the outset. These considerations should influence the
clarity of the trial protocol, the corresponding data forms
and instructions to personnel involved in data collection and
recording.
It is clear that conclusions drawn from a clinical trial
depend on the quality of the patient data collected, so it is
important that the data are accurate and complete. This is
often one aspect of any study for which external validation
by, for example, a journal referee, is not possible unless the
individual patient data are provided in a suitable format.
One consequence is that questions on data accuracy and
completeness are omitted from published checklists of the
statistical content of medical studies (Gardner et al., 1986).
In contrast such checklists ask direct questions about ran-
domisation and the study numbers necessary to provide suffi-
cient statistical power. Answers to these latter questions
should be clear and unambiguous from the text and can be
verified, at least indirectly, by a reviewer.
A central theme in the development of a successful strategy
to maintain data quality is the designation of a person (or
team) responsible for the overall co-ordination of data collec-
tion, an activity that has become entitled 'data management'.
Since effective analysis of cancer trials requires access to a
computer based statistical analysis package, data manage-
ment in a trial extends to maintenance of an accurate com-
puterised database. To achieve this, automated data quality
procedures to aid the detection, review and correction of
erroneous values are essential (Friedman et al., 1983; Kari-
son, 1981; Kronmal et al., 1978). The advent of modern
technology may now permit direct entry into the trial data
bank. Randomisation is already available through EuroCODE
(1990) to, for example, EORTC and some Cancer Research
Campaign (CRC) and Medical Research Council (MRC)
cancer trails. This facility merely re-emphasises the problem
of data quality and raises problems of security and confi-
dentiality.
Data from a multicentre clinical trial should be collected
on forms specifically designed for the trial. Typically each
patient entered has an entry form, a variable number of
follow-up forms and possibly some 'special' single forms. As
an example, consider the International Collaborative Cancer
Group (ICCG) trial of adjuvant 5- Fluorouracil, Adriamycin
and Mitomycin C in operable gastric cancer (Coombes et al.,
1990). For this trial the initial clinical data form records
demographic details and medical history of the patient, while
two 'special' forms record histology and staging of the
tumour and date of randomisation and the particular treat-
ment doses allocated. Two additional 'special' forms record
dates and details of first distant metastases and death respec-
tively. Thus there is an initial form, four special forms and
repeated follow-up forms. The forms are printed in booklets
on NCR paper and allow the top copy to be sent to the
Trials Office, where they will be processed to form a com-
puterised data base for the study in question. A duplicate
copy of the form is kept in the patients' notes.
An important determinant of success in a multicentre trial
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is the ability to give participating investigators regular in-
formation on the progress of a trial so as to maintain their
interest. This usually occurs at regular meetings of parti-
cipants at which interim reports are presented. These reports
should include the most recently collected data that have
nevertheless undergone checks for errors and inconsistencies.
This is particularly important if the trial has an associated
data monitoring committee empowered to cease recruitment
to a trial prematurely if circumstances warrant it.
The ICCG trial requires immediate feedback of untoward
toxicity to the clinicians. Other groups may wish the study
coordinators alone to be informed immediately of treatment
related deaths, perhaps particularly those associated with an
event recorded on an earlier visit form for that patient. Both
of these requirements demand rapid data entry so that all
information received at the Trials Office must be immediately
entered on the data base. In this way the latest information
on a particular patient is linked to the earlier data available
on that patient.
In anticipation of the receipt of the first complete patient
form from the clinical trial an appropriate data base has to
be prepared. This is now done for many trials conducted on
behalf of the MRC, CRC, UKCCSG and UKCCCR, using
COMPACT (COMputer PAckage for Cancer Trials) a menu
driven data management package designed on behalf of the
MRC and CRC specifically for improving the quality of data
in cancer clinical trials that involve detailed patient follow-
up.
An important feature of COMPACT is the use of a file
recording the problems arising from forms. All data, whether
correct, queried or incorrect, are entered on the computer but
those data that are queried, or are known to be incorrect
during the entry process, are automatically marked as being
suspect and details are recorded in the reserved problems file.
This avoids the accumulation of data forms which may
contain important information in the Trials Office, awaiting
replies concerning less critical items from clinical investi-
gators.
The sequence of events in setting up a trial in COMPACT
begins with a definition of the types of forms used and the
content of each form. This process is performed interactively,
and at the same time error checks can be defined. These error
checks are primarily of two types. Thus checks are used to
detect values outside defined ranges, for example, normal
haematological ranges or to verify that patients indeed satisfy
the protocol requirements for entry to the trial. In addition
checks are able to test for inconsistencies between separate
data items both within and across data forms from a partic-
ular patient.
A particularly powerful use of the consistency checking
procedure is the ability to compare values at successive visits.
The facility to make such cross checks is a strong tool for
quality control. For example, although a white blood cell
count of 4.0 x 109 1-l recorded at a particular visit would be
unlikely to violate a range check, if the same patient had had
a count of 8.0 x 109 1-l a month previously this would either
cast doubt on one of the readings or signal a rapid deteriora-
tion in the patient. Thus although both 4.0 and 8.0 x 109 1-1
would pass a range check, the combination would signal a
problem, which may or may not be an error, for that patient.
Consistency checks can be as complicated as the protocol
demands.
Examples of error checks are given in Table I for an
adjuvant breast cancer study which requires the patients to
be aged between 18 and 70 and have an initial white blood
cell count (WBC) of at least 4.0 x 1091-. There is also a
requirement that any patient experiencing weight loss of
more than 10% during treatment should be identified.
Thus the first part of Table I calculates the age of women
at randomisation and then checks if she is between 18 and 70
years of age. If she is not then a message is displayed. There
is also a check on the range for the initial WBC value. The
consistency check for weight loss, first compares the weight
at the first follow-up visit with the initial weight and cal-
culates the percentage change. For subsequent follow-up
visits (referred to as THIS visit) a comparision is made with
the previous visit (THIS-1). THIS therefore corresponds to
the actual and latest, follow-up information being entered by
the Data Manager. At the follow-up visit on 10th January
1990 patient number 1005 had recorded a 20% weight loss
since the previous follow-up visit.
Thus such checks can be used to identify patients that the
protocol specifies require the Trial Co-ordinator's, rather
than just the Data Managers, immediate attention. For
example, those who receive a modified dosage schedule, or
experience a particular form of unexpected toxicity or as in
the above example a serious weight loss. Once the forms and
checks are defined, interactive data entry can begin. In COM-
PACT this is carried out by selection from a menu of items
until the relevant form for the particular patient is identified.
The items on the form are then displayed one at a time and
the data directly input. The data input program is designed
for ease of use by those without computer programming
expertise. Should a data item entered violate an error check,
the system generates a REJECT message. This immediately
alerts the Data Manager to check the entry made against the
paper form. Should the item actually recorded on the form
provoke a major range or consistency violation or if the data
item is missing, this is recorded in the separate PROBLEMS
file, and the patient data file is flagged at an appropriate
point.
At the end of the data entry session the PROBLEMS file
can be inspected and appropriate action taken. It is usually
the case in practice that many of these problems can be easily
resolved with the participating centre, perhaps by a telephone
call, and the Data Manager will enter the corrected values at
the next data entry session. Ifthese new values do not violate
range or consistency checks, the system automatically deletes
the relevant entry in the PROBLEMS file. In some circum-
stances a flag can be entered in the PROBLEMS file indicat-
ing in effect, 'This is an apparently abnormal value, that lies
outside our range checks but we have verified with the inves-
tigator who confirms that it is abnormal but correct.' Once
flagged in this way future error messages about this value will
be automatically suppressed and the value passed to the main
data file. Such a device leaves an appropriate explanation of
the apparent anomaly on the data file for future reference. At
any stage such aberrant values can be displayed from the
PROBLEMS file if appropriate.
The PROBLEMS file is a unique feature of COMPACT
which is not available in other data management software
since most have not been designed specifically for clinical
trial use.
Another important aspect of trial management is checking
that patients are seen regularly and that their progress
reports are returned on schedule. COMPACT provides the
facility to check the most complex of follow-up schedules,
and signal overdue information. Thus the later part of Table
I shows that the visit on 10 March 1990 for patient number
1005 was not at the schedule anticipated of 6 weeks following
her previous visit of 10 January 1990.
COMPACT has been designed to act an an interface
between the clinical trial data and standard statistical
analysis packages. However, most statistical packages can
only process rectangular (flat) data files while the data col-
lected in a clinical trial are always 'ragged', because patients
enter a trial at different times and have different numbers of
follow-up visits depending on the length of their survival.
When COMPACT generates an output data file for analysis
it also automatically produces the appropriate data descrip-
tion and format required for the particular statistical package
and the specified variables of interest for analysis. This
facility substantially reduces the amount of programming
involved in producing an analysis. It can also select partic-
ular subgroups of patients or follow-up examinations and
derive new variables, such as patient survival time from
randomisation both for patients who have died and for those
still alive (censored). If repeat analyses are to be carried out
for successive collaborators meetings, perhaps to report on
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data file and output specifications can be regenerated using
the stored instructions from the first analysis.
An example of commands for the calculation of survival
time and the creation of an analysis file for ultimate transfer
to a statistical package is given in Table II. Thus if patients
are still alive the latest date known to be alive will either be
on the last follow-up form (referred to as LEXAM) or on the
relapse form. For those patients who have died the date of
death is recorded on a separate 'death' form.
There are many facets that govern the quality of data
submitted to a trials office: these include the clarity of the
data forms, the level of enthusiasm of the participants and
the nature of the information requested. While we have not
discussed these aspects in detail they are important and must
not be overlooked. Mistakes and omissions in the data are
bound to occur, however well designed the trial and however
conscientious the investigators.
Some organisations, for example the EORTC and some of
the Cooperative Groups in the USA, have established data
quality committees. These are concerned not only about the
quality of the treatment actually given, for example how
closely the investigators adhere to the study protocol, but
how the contents of the patient records and study data forms
compare. Such committees are not discussed in detail here.
However important their role, it is clear that they can only sample 'quality' from time to time. In contrast, most would
agree that rapid data entry, with associated immediate signal- ling of queries on a daily basis, is a vital component of
overall data quality.
It is our view that data entry to a clinical trial is best done, patient form by patient form, by a Data Manager who is
conversant with the trial protocol and who is also responsible
for reporting on the progress of the trial to the investigators.
Thus the data will be entered by someone who knows the
study intimately, the individual patients, albeit indirectly, and
the data checking facilities themselves will have been designed with their assistance and experience from other trials. This is
perhaps one of the most important guarantees ofdata quality.
Table I Error checks for an adjuvant breast cancer trial
Checks- range
COMPACT code* COMPACT message if check is violated
AGE= TRUNC ((DOR - DOB)/365.25)
IF AGE NOTIN (18-70)
REJECT 'Patient aged = ',AGE,' - protocol violation' 'Patient aged = 72 - protocol violation'
IF WBCINIT LT 4.0
REJECT 'Initial WBC = ',WBCINIT,' - protocol violation' 'Initial WBC = 3.2 - protocol violation'
Checks - consistency
COMPACT code* COMPACT message if check is violated
CHWT= WTINIT - WTFU(1)
CW= WTFU(THIS-1) - WTFU(THIS)
PERC = (CHWT/WTINIT)*100
PCTW= (CW/WTFU(THIS-1))*100
IF(ABS(PERC) GE 10.5) AND (FU(1) EQ '1')
REJECT 'Weight change> 10% Initial = ',WTINIT, 'kg.
Present = ',WTFU(l),'kg.'
IF ABS(PCWi) GE 10.5
REJECT 'Weight change> 10%
Previous= ',WTFU(THIS-l),'kg, Present= ',WTFU(THIS),'kg ID Visit date
Change= ', PWCT,'%' 1005 10.01.90 Weight change>10%,
Previous = 70 kg, Present = 56 kg
Change = 20%
Checks- schedule
COMPACT code* COMPACT message ifcheck is violated
DELAY= VISIT(THIS)-VISIT(THIS-1)
IF (DELAY>42) AND (TREAT EQ '1')
REJECT DELAY,' days between visits for patient receiving ID Visit date
Treatment 1, too long' 1005 10.03.90 59 days between visits for patients receiving
Treatment 1, too long
*COMPACT variable names in BOLD, derived variable names in ITALICS.
DOR = Date of randomisation. WBCINIT = Initial WCB count. DOB = Date ofbirth. WTINIT = Initial weight. VISIT = Date of visit. WTFU = Weight at follow-up examination FU = Visit number. ID = Patient identifier.
Table II Commands to calculate survival time for an adjuvant breast cancer study
COMPACT code* Comment
DLS = MAX (DREL,DFU(LEXAM)) Calculate latest date that patients were seen alive (whether at most recent routine follow-up or at
relapse)
IF DOD NE MISS
BEGIN
SURV= DOD - DOR
STATUS= I
ELSE
SURV= DLS- DOR
STATUS=0
ENDIF
Calculating survival times and calculating status variable
- For patients who have died (STATUS = 1), survival time is from randomisation to death
- For patients who are alive (STATUS = 0), survival time is from randomisation to the date they
were last known to be alive and is censored
FILE ID, TREAT, SURV, STATUS Output derived data with relevant variables to a file for statistical analysis
*COMPACT variables names in BOLD, derived names in ITALICS
DOR = Date of randomisation DOD = Date of death
DFU = Date offollow-up (repeated) ID = Patient identifier
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In some situations batch entry is unavoidable. For exam-
ple, in very large trials with large numbers of patient forms
arriving daily the data are often entered into the computer
file by a 'Keypunch Operator' rather than a 'Data Manager'.
In these circumstances patient form by patient form checking
procedures at data entry may be entirely absent or at least
will be less efficient, perhaps resulting in a proportionally
larger number of queries being generated. However such data
can be entered into COMPACT in batch mode, and the
resulting queries addressed by means of the PROBLEMS file.
The increasing awareness of the need for larger collabora-
tive trials for certain tumour types has resulted in cooperative
group trials, and they may be organised in such a way that
there is more than one Trials Office involved in the random-
isation and data management processes. Such collaboration
demands a uniform pattern of data checking and data files
that are transferable between sites.
For large studies automated quality control is essential and
many Trials Offices have developed their 'in-house' methods
for this purpose. The computer software for these systems,
however, has generally not been transferable to other work-
ing environments. This contrasts sharply with the widespread
use of standard statistical analysis packages which have been
available on a wide range of computers for many years.
There are considerable advantages in using a tried and tested
data management package rather than writing software for
every new trial, which is an expensive and time consuming
operation.
Most data management packages that can be purchased
have not been designed specifically for clinical trial use. They
tend either to be large, expensive and available only on large
computers, or rather basic, resulting in the need for con-
siderable extra development. Most are also difficult for inex-
perienced computer users. Moreover, we are not aware of
any with the vital PROBLEMS and longitudinal data facil-
ities or adequate means of dealing with missing data.
COMPACT has been written with cancer trials in mind
and certain fundamental aspects of good clinical trial practice
are embedded in the package. Thus there are facilities to
monitor the incoming data and provide rapid feedback to the
trial co-ordinator, enabling corrective action to be taken
when problems arise. One can equally well use COMPACT
for Phase II trials in cancer, for trials of treatment for other
diseases, or for other types of clinical or laboratory studies
requiring follow-up. COMPACT has also been successfully
used for epidemiological studies and for teaching purposes in
courses involving clinicans and medical statisticians.
There are no constraints on the number of patients that
can be entered into a study using COMPACT, apart from
overall disc capacity on the computer being used. On a micro
computer running MS-DOS, where memory is limited, up to
eight forms, 300 variables and 20 visits are possible. There is
a detailed user manual. COMPACT is currently in use at ten
centres in the United Kingdom running in excess of 100
clinical trials, more than half of which are in cancer. A
second generation version of COMPACT is under develop-
ment.
We believe that COMPACT is particularly suitable for use
in smaller Trials Offices where adequate computer program-
mer support cannot be provided to develop an 'in-house'
system. COMPACT can be up and running for a new trial in
a matter of days, the exact time depending on the experience
of the programmer or data manager and the complexity of
the trials forms and follow-up schedules. Organisers of new
studies should consider COMPACT before they go to the
expense of developing their own computer software. It is
available at low cost for CRC and MRC supported groups.
Information about availability and support for users may be
obtained from J.M. Bliss.
COMPACT has received support from the Cancer
Research Campaign and the Medical Research Council.
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